Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders
Launched by LILLE CATHOLIC UNIVERSITY · May 16, 2022
Trial Information
Current as of July 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how common mast cell activation syndrome (MCAS) is in patients who have hypermobile Ehlers-Danlos syndrome (hEDS) and also experience digestive issues. The goal is to understand the connection between these two conditions better, particularly in patients receiving care in allergy departments.
To participate, individuals must be 14 years or older and diagnosed with hEDS and digestive disorders. Participants should be able to answer questionnaires and be willing to have their health information used for research. Those who have recently taken high doses of certain antihistamines or are under guardianship are not eligible. If you choose to take part, you’ll likely help researchers learn more about these conditions, which could lead to better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • with hypermobile Ehlers Danlos syndrome
- • with digestive disorders
- • 14 years of age or older (minimum age for the MOS-SF 36 questionnaire)
- • able to answer the questionnaires
- • whose participation in a day hospital at Saint Vincent de Paul dedicated to the assessment of "functional digestive pain" is planned
- • who do not object to the use of their health data for research purposes
- Additional criteria for minors :
- • - No objection to the use of health data for research purposes by parents/guardians
- Exclusion Criteria:
- • under guardianship or curatorship
- * having taken a long-term high-dose antihistamine treatment (H1 or H2) during the last two months, according to the following thresholds :
- • Desloratadine (\>5 mg/jour)
- • Bilastine (\>20 mg/jour)
- • Cetirizine (\>20 mg/jour)
- • Ebastine (\>10 mg/jour)
- • Fexofenadine (\>150 mg/jour)
- • Levocetirizine (\>5 mg/jour)
- • Loratadine (\>10 mg/jour)
- • Exocetiridine (5 mg/jour)
- • Mizolastine (\>10 mg/jour)
- • Rupatadine (\>10 mg/jour)
- • Polaramine (\>10 mg/jour)
- • Oxomemazine (\>2 mg/jour)
- • Hydroxyzine (\>25 mg/jour)
- • Doxylamine (\>15 mg/jour)
- • Cimetidine (\>200 mg/jour)
- • Patients deprived of liberty, pregnant or nursing women
About Lille Catholic University
Lille Catholic University, a prominent academic institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university integrates expertise from various fields to foster the development of cutting-edge medical solutions. Its commitment to ethical standards and patient-centered approaches ensures that clinical trials conducted under its auspices are rigorous, scientifically sound, and aligned with the highest standards of care. By leveraging its extensive network of researchers, healthcare professionals, and resources, Lille Catholic University plays a vital role in contributing to the enhancement of medical knowledge and the improvement of patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, Nord, France
Patients applied
Trial Officials
Juliette CARON, Md
Principal Investigator
Lille Catholic University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials